Literature DB >> 87267

Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages.

G Poste, R Kirsh.   

Abstract

The ability of inflammatory tissue macrophages harvested on glass coverslips implanted in the s.c. tissue of C57BL/6 mice to kill tumor cells in vitro has been examined. Macrophage present on coverslips implanted for less than 4 days are devoid of spontaneous tumoricidal activity but can be rendered cytotoxic for syngeneic and allogeneic tumor cells in vitro by incubation in vitro with lymphokines release by mitogen-stimulated lymphocytes. Inflammatory macrophages on coverslips implanted for 4 to 7 days show significant spontaneous cytotoxicity for tumor cells in vitro, and their tumoricidal activity is further increased by additional incubation in vitro with lymphokines. With progression, the inflammatory macrophages harvested on coverslips implanted for longer than 7 days lack spontaneous cytotoxic activity and are also resistant to activation by lymphokines in vitro. These alterations in tumoricidal activity and responsiveness to lymphokines are accompanied by a marked reduction in the number of peroxidase-positive macrophages within the population, suggesting that maintenance of tumoricidal activity requires continuous influx of new peroxidase-positive macrophages from the circulation. Previously activated macrophages which have lost their tumoricidal activity and become refractory to reactivation by lymphokines in the extracellular environment can be reactivated by treatment in vitro with liposomes containing encapsulated lymphokines.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 87267

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Inhibition of tumor metastasis by carrageenan-induced granulomas.

Authors:  W J Kort; A M Bijma; I M Hekking
Journal:  Clin Exp Metastasis       Date:  1989 Jan-Feb       Impact factor: 5.150

Review 2.  Macrophage infiltration and tumor progression.

Authors:  S J Normann
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 3.  Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease.

Authors:  I J Fidler; G Poste
Journal:  Springer Semin Immunopathol       Date:  1982

Review 4.  Therapy of disseminated melanoma by liposome-activated macrophages.

Authors:  I J Fidler
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

5.  Changes in the macrophage content of lung metastases at different stages in tumor growth.

Authors:  P J Bugelski; R L Kirsh; J M Sowinski; G Poste
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

6.  Macrophage polykaryon formation in vitro by peritoneal cells from mice given injections of sodium periodate.

Authors:  J B Weinberg
Journal:  Am J Pathol       Date:  1983-02       Impact factor: 4.307

7.  Macrophages and multicellular tumor spheroids in co-culture: a three-dimensional model to study tumor-host interactions. Evidence for macrophage-mediated tumor cell proliferation and migration.

Authors:  S Hauptmann; G Zwadlo-Klarwasser; M Jansen; B Klosterhalfen; C J Kirkpatrick
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

8.  Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages.

Authors:  A Biondi; G Peri; N Colombo; G Bolis; A Mantovani
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

9.  Activated human monocytes inhibit the intracellular multiplication of Legionnaires' disease bacteria.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

10.  Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.

Authors:  E S Kleinerman; A J Schroit; W E Fogler; I J Fidler
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.